Levi & Korsinsky Announces an Investigation on Behalf of Supernus Pharmaceuticals, Inc. (SUPN) Shareholders Who May Have Been Affected by Fraud
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Supernus Pharmaceuticals, Inc. (SUPN) for potential violations of federal securities laws following the failure of a Phase 2b study for SPN-820 in treatment-resistant depression.
March 12, 2025 | 11:45 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Supernus Pharmaceuticals is under investigation by Levi & Korsinsky for potential securities law violations after its SPN-820 study failed to meet primary endpoints.
The investigation by Levi & Korsinsky into potential securities law violations is significant, especially following the failure of a key clinical trial. This could lead to legal challenges and affect investor confidence, likely impacting the stock negatively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100